Sweden's Apotea Q2 revenue rises on steady growth
Sweden's Apotea Q2 revenue rises on steady growth
Overview
Sweden online pharmacy's Q2 net revenue rose 10.9% yr/yr
Adjusted EBIT for Q2 increased, but margin slipped to 5.2% from 5.4%
Company expanded sales in Norway and saw strong growth in own brands
Outlook
Company says growth initiatives will take time to impact future results
Result Drivers
NORWAY EXPANSION - Co began scaling up sales of beauty and health products in Norway through apotea.no
OWN BRANDS GROWTH - Strong growth in own brands, now generating annual sales of more than SEK 100 mln
Company press release: ID:nMFN2s9h7b
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Revenue |
| SEK 2.03 bln |
|
Q2 Net Income |
| SEK 81.10 mln |
|
Q2 Cash Flow from Operating Activities |
| SEK 76.80 mln |
|
Q2 EBIT |
| SEK 104.40 mln |
|
Q2 EBIT Margin |
| 5.20% |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy"
Wall Street's median 12-month price target for Apotea AB (publ) is SEK84.00, about 14% above its July 16 closing price of SEK73.70
The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 23 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)